You are here: Home » Current Affairs » Coronavirus » News
Business Standard

Sputnik V approved, India to soon have more Covid vaccines: Things to know

Tune in to know about India's third Covid vaccine, Sputnik V, its efficacy, cost, dose duration, among other things

Coronavirus Vaccine | Coronavirus

Kanishka Gupta  |  New Delhi 

Sputnik Covid-19 vaccine
Photo: Reuters


Covaxin showed 81% interim efficacy: Bharat Biotech on Phase 3 results

Coronavirus vaccine update: Serum vs volunteer fight, PM calls meet, & more

Adverse effect of Covid-19 vaccine: What the law says, or doesn't

India Coronavirus Dispatch: What does '90% efficacy' for a vaccine mean?

Bharat Biotech to have phase 3 efficacy data for Covaxin in 2 weeks

  • India will soon have many more vaccines against as the government is speeding up emergency approvals for foreign-made vaccines that have been granted emergency use authorisation (EUA) in other countries.

    This is being done to expand the basket of vaccines for domestic use and hasten the pace and coverage of vaccination.

    In this podcast, we will discuss all about India’s third Covid vaccine, Sputnik V, its efficacy, cost, dose duration, among other things. We will also talk about the efficacy of Covishield and Covaxin against different variants of .

    Tune in for more

    Subscribe to Business Standard Premium

    Exclusive Stories, Curated Newsletters, 26 years of Archives, E-paper, and more!

    Insightful news, sharp views, newsletters, e-paper, and more! Unlock incisive commentary only on Business Standard.

    Download the Business Standard App for latest Business News and Market News .

    First Published: Tue, April 13 2021. 14:40 IST